MedTrace Logo

A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396

NCT04246190 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-02-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of CKD-396.

Conditions

  • Type2 Diabetes Mellitus

Interventions

DRUG

CKD-501 and D759

Reference drug, CKD-501 1T and D759 1T, QD, PO

DRUG

CKD-396

Reference drug, CKD-396 1T, QD, PO

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Min Soo Park, Ph.D. M.D · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-24
Primary Completion
2020-04-10
Completion
2020-07-16

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04246190 on ClinicalTrials.gov